15th anniversary of rebamipide: Looking ahead to the new mechanisms and new applications

Digestive Diseases and Sciences

Volumn 50, Issue SUPPL. 1, 2005, Pages

  Arakawa, Tetsuo ^a   Higuchi, Kazuhide ^a   Fujiwara, Yasuhiro ^a   Watanabe, Toshio ^a   Tominaga, Kazunari ^a   Sasaki, Eiji ^a   Oshitani, Nobuhide ^a   Yoshikawa, Toshikazu ^b   Tarnawski, Andrzej S ^c  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Cytokine; Growth factor; H. pylori; NSAIDs; Peptic ulcer; Prostaglandin

Indexed keywords

AMOXICILLIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CIMETIDINE; GROWTH FACTOR; HEAT SHOCK PROTEIN; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN SYNTHASE; PROTON PUMP INHIBITOR; REBAMIPIDE; STOMACH SECRETION INHIBITOR;

ABDOMINAL PAIN; ABORTION; BACTERIAL INFECTION; CANCER PREVENTION; CELL PROTECTION; CHEMOPROPHYLAXIS; CHROMOENDOSCOPY; CHRONIC GASTRITIS; CLINICAL TRIAL; DIARRHEA; DRUG COST; DRUG MECHANISM; DUODENUM ULCER; ERADICATION THERAPY; HELICOBACTER PYLORI; HUMAN; INTERMETHOD COMPARISON; JAPAN; MORTALITY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PEPTIC ULCER; PRIORITY JOURNAL; PROCTITIS; QUALITY CONTROL; REVIEW; STOMACH ACID SECRETION; STOMACH CANCER; STOMACH MUCOSA LESION; STOMACH ULCER; ULCER HEALING;

ALANINE; ANTI-ULCER AGENTS; ANTIOXIDANTS; CHEMOPREVENTION; GROWTH SUBSTANCES; HUMANS; PEPTIC ULCER; QUINOLONES; RANDOMIZED CONTROLLED TRIALS; WOUND HEALING;

EID: 25644439918     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-005-2800-9     Document Type: Review

References (56)

1. Takemoto T, Namiki M, Yachi A, Masamune O, Ishikawa M, Goto Y, Kimura K, Itoh S, Matsuo Y, Kobayashi M, Oka H, Tsuchiya M, Kurokawa K, Yokoyama I, Okabe H, Miwa T, Kohli Y, Nakazawa S, Takeuchi T, Uchino H, Miyake T, Kawai K, Kamada T, Kobayashi K, Ohshiba S, Tsuji T, Kajiyama G, Shimada Y, Okazaki Y, Kishi S, Nawata H, Tanikawa K, Hayakawa H, Hashimoto S: Effect of rebamipide (OPC-12759) on gastric ulcer healing multicenter, double-blind, cetraxate controlled clinical study. Rinsho Seijin-byo 19:1265-1291, 1989
2. Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A: Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci 43(Suppl):5S-13S, 1998
3. Kleine A, Kluge S, Peskar BM: Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci 38:1441-1449, 1993
4. Yoshikawa T, Naito Y, Tanigawa T, Kondo M: Free radical scavenging activity of the novel anti-ulcer agent rebamipide studied by electron spin resonance. Arzneimittelforschung 43:363-366, 1993
5. Naito Y, Yoshikawa T, Tanigawa T, Sakurai K, Yamasaki K, Uchida M, Kondo M: Hydroxyl radical scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Free Radic Biol Med 18:117-123, 1995
6. Yoshikawa T, Arakawa T: Bioregulation and its Disorders in the Gastrointestinal Tract. Tokyo, Blackwell Science, 1998
7. Nebiki H, Arakawa T, Higuchi K, Kobayashi K: Quality of ulcer healing influences the relapse of gastric ulcers in humans. J Gastroenterol Hepatol 12:109-114, 1997
8. Arakawa T, Nebiki H, Uchida T, Kimura S, Higuchi K, Kobayashi K: Clinical assessment of quality of ulcer healing - a new concept to rank healed peptic ulcer. Eur J Gastroenterol Hepatol 5(Suppl 3):S87-S92, 1993
9. Higuchi K, Arakawa T, Nebiki H, Uchida T, Fujiwara Y, Ando K, Yamasaki K, Takaishi O, Fukuda T, Kobayashi K, Kuroki T: Rebamipide prevents recurrence of gastric ulcers without affecting Helicobacter pylori status. Dig Dis Sci 43(Suppl):S99-S106, 1998
10. Arakawa T, Watanabe T, Fukuda T, Higuchi K, Takaishi O, Yamasaki K, Kobayashi K, Tarnawski A: Indomethacin treatment during initial period of acetic acid-induced rat gastric ulcer healing promotes persistent polymorphonuclear cell-infiltration and increase future ulcer recurrence. Dig Dis Sci 41:2055-2061, 1996
11. Watanabe T, Arakawa T, Fukuda T, Higuchi K, Kobayashi K: Role of neutrophils in a rat model of gastric ulcer recurrence caused by interleukin-1 beta. Am J Pathol 150:971-979, 1997
12. Watanabe T, Higuchi K, Tominaga K, Fujiwara Y, Arakawa T: Acid regulates inflammatory response in a rat model of induction of gastric ulcer recurrence by interleukin 1beta. Gut 48:774-781, 2001
13. Watanabe T, Higuchi K, Hamaguchi M, Shiba M, Tominaga K, Fujiwara Y, Matsumoto T, and Arakawa T: Monocyte chemotactic protein-1 regulates leukocyte recruitment during gastric ulcer recurrence induced by tumor necrosis factor-α. Am J Physiol Gastrointest Liver Physiol 287:G919-G928, 2004
14. Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G: Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 112:1442-1447, 1997
15. Befrits R, Sjostedt S, Odman B, Sorngard H, Lindberg G: Curing Helicobacter pylori infection in patients with duodenal ulcer does not provoke gastroesophageal reflux disease. Helicobacter 5:202-205, 2000
16. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT: Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 121:1120-1126, 2001
17. Azuma T, Suto H, Ito Y, Ohtani M, Dojo M, Kuriyama M, Kato T: Gastric leptin and Helicobacter pylori infection. Gut 49:324-329, 2001
18. Fujiwara Y, Higuchi K, Arafa UA, Uchida T, Tominaga K, Watanabe T, Arakawa T: Long-term effect of Helicobacter pylori eradication on quality of life, body mass index, and newly developed diseases in Japanese patients with peptic ulcer disease. Hepatogastroenterology 49:1298-1302, 2002
19. Takaishi O, Arakawa T, Fujiwara Y, Fukuda T, Otani K, Yamasaki K, Higuchi K, Kuroki T: Inhibition by 16,16-dimethyl prostaglandin E2 of tumor necrosis factor-alpha and interleukin-1beta production and messenger RNA expression in human monocytes stimulated by Helicobacter pylori. Dig Dis Sci 44:2405-2411, 1999
20. Haruma K, Ito M: Review article: clinical significance of mucosal-protective agents: acid, inflammation, carcinogenesis and rebamipide. Aliment Pharmacol Ther 18(Suppl 1):153-159, 2003
21. Aihara M, Azuma A, Takizawa H, Tsuchimoto D, Funakoshi Y, Shindo Y, Ohmoto Y, Imagawa K, Kikuchi M, Mukaida N, Matsushima K: Molecular analysis of suppression of interleukin-8 production by rebamipide in Helicobacter pylori-stimulated gastric cancer cell lies. Dig Dis Sci 43(Suppl):174S-180S, 1998
22. Naito Y, Yoshikawa T, Iinuma S, Yagi N, Matsuyama K, Boku Y, Fujii T, Yoshida N, Kondo M, Sasaki E: Rebamipide protects against Indomethacin-induced gastric mucosal injury in healthy volunteers in a double-blind, placebo-controlled study. Dig Dis Sci 43(Suppl):83S-89S, 1998
23. Sun WH, Tsuji S, Tsujii M, Gunawan ES, Kawai N, Kimura A, Kakiuchi Y, Yasumaru M, Iijima H, Okuda Y, Sasaki Y, Hori M, Kawano S: Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agent. J Pharmacol Exp Ther 295:447-452, 2000
24. Suetsugu H, Ishihara S, Moriyama N, Kazumori H, Adachi K, Fukuda R, Watanabe M, Kinoshita Y: Effect of rebamipide on prostaglandin EP4 receptor gene expression in rat gastric mucosa. J Lab Clin Med 136:50-57, 2000
25. Tarnawski A, Arakawa T, Kobayashi K: Rebamipide treatment activates epidermal growth factor and its receptor expression in normal and ulcerated gastric mucosa in rats: one mechanism for its ulcer healing action? Dig Dis Sci 43(Suppl):90S-98S, 1998
26. Udagawa A, Shiota G, Ichiba M, Murawaki Y: Effect of rebamipide on acetic acid-induced gastric ulcer in rats: involvement of hepatocyte growth factor. Scand J Gastroenterol 38:141-146, 2003
27. Watanabe T, Higuchi K, Hamaguchi M, Tanigawa T, Wada R, Tominaga K, Fujiwara Y, Arakawa T: Rebamipide prevents delay of acetic acid-induced gastric ulcer healing caused by Helicobacter pylori infection in Mongolian gerbils. Dig Dis Sci 47:1582-1589, 2002
28. Tarnawski AS, Chai J, Pai R, Chiou SK: Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci 49:202-209, 2004
29. Tsukimi Y, Fujishita T, Nakajima K, Okabe S: Effect of rebamipide on cell death induced by combined treatment of mild heat shock and quercetin in RGM-1 cells: a role for HSP70 induction. Pharmacology 64:28-35, 2002
30. Takaishi O, Arakawa T, Yamasaki K, Fujiwara Y, Uchida T, Tominaga K, Watanabe T, Higuchi K, Fukuda T, Kobayashi K, Kuroki T: Protective effect of rebamipide against ammonia-induced gastric mucosal lesions. Dig Dis Sci 43 (Suppl):78S-82S, 1998
31. Kim H, Seo JY, Kim KH: Inhibition of lipid peroxidation, NF-kappaB activation and IL-8 production by rebamipide in Helicobacter pylori-stimulated gastric epithelial cells. Dig Dis Sci 45:621-628, 2000
32. Makiyama K, Takeshima F, Kawasaki H, Zea-Iriarte WL: Anti-inflammatory effect of rebamipide enema on proctitis type ulcerative colitis: a novel therapeutic alternative. Am J Gastroenterol 95:1838-1839, 2000
33. Farhadi A, Keshavarzian A, Fitzpatrick LR, Mutlu E, Zhang Y, Banan A: Modulatory effects of plasma and colonic milieu of patients with ulcerative colitis on neutrophil reactive oxygen species production in presence of a novel antioxidant, rebamipide. Dig Dis Sci 47:1342-1348, 2002
34. Hayashi S, Sugiyama T, Amano K, Isogai H, Isogai E, Aihara M, Kikuchi M, Asaka M, Yokota K, Oguma K, Fujii N, Hirai Y: Effect of rebamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells. Antimicrob Agents Chemother 42:1895-1899, 1998
35. Yoshida N, Yoshikawa T, Iinuma S, Arai M, Takenaka S, Sakamoto K, Miyajima T, Nakamura Y, Yagi N, Naito Y, Mukai F, Kondo M: Rebamipide protects against activation of neutrophils by Helicobacter pylori. Dig Dis Sci 41:1139-1144, 1996
36. Matysiak-Budnik T, de Mascarel A, Abely M, Mayo K, Heyman M, Megraud F: Positive effect of rebamipide on gastric permeability in mice after eradication of Helicobacter felis. Scand J Gastroenterol 35:470-175, 2000
37. Hong WS, Jung HY, Yang SK, Myung SJ, Kim JH, Min YI, Chung MH, Lee HS, Kim HW: The antioxidant effect of rebamipide on oxygen free radical production by H. pylori-activated human neutrophils: in comparison with N-acetylcysteine, ascorbic acid and glutathione. Pharmacol Res 44:293-297, 2001
38. Haruma K, Ito M, Kido S, Manabe N, Kitadai Y, Sumii M, Tanaka S, Yoshihara M, Chayama K: Long-term rebamipide therapy improves Helicobacter pylori-associated chronic gastritis. Dig Dis Sci 47:862-867, 2002
39. Murakami K, Okajima K, Harada N, Isobe H, Okabe H: Rebamipide prevents indomethacin-induced gastric mucosal lesion formation by inhibiting activation of neutrophils in rats. Dig Dis Sci 43(Suppl):139S-142S, 1998
40. Yamasaki K, Arakawa T, Takaishi O, Higuchi K, Kobayashi K, Kuroki T: Influence of rebamipide on indometacin-induced gastric hemorrhage in rats under restraint stress. Arzneimittelforschung 49:359-365, 1999
41. Kim CD, Kim YK, Lee SH, Hong KW: Rebamipide inhibits neutrophil adhesion to hypoxia/reoxygenation-stimulated endothelial cells via nuclear factor-kappaB-dependent pathway. J Pharmacol Exp Ther 294:864-869, 2000
42. Kobayashi T, Zinchuk VS, Garcia del Saz E, Jiang F, Yamasaki Y, Kataoka S, Okada T, Tsunawaki S, Seguchi H: Suppressive effect of rebamipide: an antiulcer agent, against activation of human neutrophils exposed to formyl-methionyl-leucyl-phenylalanine. Histol Histopathol 15:1067-1076, 2000
43. Nagano C, Azuma A, Ishiyama H, Sekiguchi K, Imagawa K, Kikuchi M: Rebamipide suppresses formyl-methionyl-leucyl-phenylalanine (fMLP)-induced superoxide production by inhibiting fMLP-receptor binding in human neutrophils. J Pharmacol Exp Ther 297:388-394, 2001
44. Higuchi K, Tanigawa T, Hamaguchi M, Takashima T, Sasaki E, Shiba M, Tominaga K, Fujiwara Y, Oshitani N, Matsumoto T, Watanabe T, Arakawa T: Comparison of the effects of rebamipide with those of cimetidine on chronic gastritis associated with Helicobacter pylori in Mongolian gerbils. Aliment Pharmacol Ther. 18(Suppl 1):1-7, 2003
45. Hahm KB, Kim DH, Lee KM, Lee JS, Surh YJ, Kim YB, Yoo BM, Kim JH, Joo HJ, Cho YK, Nam KT, Cho SW: Effect of long-term administration of rebamipide on Helicobacter pylori infection in mice. Aliment Pharmacol Ther 18(Suppl 1):24-38, 2003
46. Tarnawski A, Pai R, Chiou SK, Chai J, Chu EC: Rebamipide inhibits gastric cancer growth by targeting survivin and Aurora-B. Biochem Biophys Res Commun 334:207-212, 2005
47. Wong BC, Chang FY, Abid S, Abbas Z, Lin BR, Van Rensburg C, Chen PC, Schneider H, Simjee AE, Hamid SS, Seebaran A, Zhang J, Destefano M, Lam SK: Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. Aliment Pharmacol Ther 14:1529-1535, 2000
48. Lai KC, Hui WM, Wong BC, Hu WH, Lam SK: Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage. Aliment Pharmacol Ther 14:1071-1076, 2000
49. Higuchi K, Fujiwara Y, Tominaga K, Watanabe T, Shiba M, Nakamura S, Oshitani N, Matsumoto T, Arakawa T: Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori? A randomized, controlled, prospective study. Aliment Pharmacol Ther 17:111-117, 2003
50. Terano A et al.: A new combination therapy for gastric ulcer: a preliminary study of Helicobacter pylori eradication triple therapy followed by gastroprotective treatment with rebamipide. J Gastroenterol Hepatol, in press
51. Matsuda T, Ohno S, Hirohata S, Miyanaga Y, Ujihara H, Inaba G, Nakamura S, Tanaka S, Kogure M, Mizushima Y: Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet's disease: a randomised, double-blind, placebo-controlled study. Drugs Res Dev 4:19-28, 2003
52. Ro JY, Kim JY, Kim KH: The inhibitory mechanism of rebamipide on the mediator release in the guinea pig lung mast cells activated with specific antigen-antibody reactions. Pharmacology 63:175-184, 2001
53. Saad SY, Najjar TA, Al-Sohaibani MO: The effect of rebamipide on cisplatin-induced nephrotoxicity in rats. Pharmacol Res 42:81-86, 2000
54. Hong KW, Kim KE, Rhim BY, Lee WS, Kim CD: Effect of rebamipide on liver damage and increased tumor necrosis factor in a rat model of endotoxin shock. Dig Dis Sci 43(Suppl):154S-159S, 1998
55. Kishimoto S, Haruma K, Tari A, Sakurai K, Nakano M, Nakagawa Y: Rebamipide, an antiulcer drug, prevents DSS-induced colitis formation in rats. Dig Dis Sci 45:1608-1616, 2000
56. Urashima H, Okamoto T, Takeji Y, Shinohara H, Fujisawa S: Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model. Cornea 23:613-619, 2004